Navigation Links
Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
Date:9/8/2011

ch differ by only two nucleotides, are intronic microRNAs located within the sterol response element binding protein genes SREBF2 and SREBF1, respectively, which code for transcription factors that regulate cholesterol and fatty acid metabolism. Recent studies have shown that miR-33a/b regulates the cholesterol and fatty acid pathways in a negative feedback loop.  miR-33/b represses the cholesterol transporter ABCA1 resulting in decreased cellular cholesterol efflux to HDL-C and reverse cholesterol transport. Inhibition of miR-33 in mice, which only have miR-33a, resulted in enhanced cholesterol transport and reduction of atherosclerotic plaques (Rayner et al., J Clin Invest doi:10.1172/JCI57275). miR-33a/b also suppresses key enzymes involved in the oxidation of fatty acids resulting in the accumulation of triglycerides. Inhibition of miR-33a/b increases fatty acid oxidation and insulin signaling (Davalos et al., PNAS doi:10.1073/pnas.1102281108). These studies suggest that an anti-miR33a/b oligonucleotide treatment may be a promising strategy to treat metabolic disease.  

miR-21.  Regulus is developing microRNA therapeutics targeting miR-21 using proprietary chemically modified anti-miR oligonucleotides delivered systemically. Recent studies have demonstrated that miR-21 is overexpressed in many cancer types (Volinia et al., PNAS. 2006) and can promote tumor progression and metastasis (Medina et al., Nature. 2010). Regulus data has shown that miR-21 is upregulated in patients with hepatocellular carcinoma (HCC). In preclinical models of HCC, short term treatment (2-3 weeks) with anti-miR-21 inhibited miR-21 in the liver and reduced liver tumor formation. Longer term treatment (17 weeks) with anti-miR-21 resulted in a significant survival advantage (p<0.0001) over saline and control anti-miR treated mice. These findings suggest that miR-21 is a promising target for cancer.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
(Date:12/20/2014)... 2014 BambooIndustry.com is a professional company ... The business has recently shown its new engineered bamboo ... its bamboo flooring models. , BambooIndustry.com’s customers come from ... and more. According to the CEO of the company, ... fast in the past few years, and the demand ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection ... of special occasion dresses for the coming new year. ... occasion dresses for global women. Now, all the models ... to 80% off. Among the new items, the model ... Dress) is very popular. What’s more, Weddingshe.com also provides ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress ... Sale Online for 2015. Great discounts are now ... old consumers can get a discount, up to 80% ... website before January 30, 2015. , VogueQueen.com has recently ... a prom dress promotion. Many customers worldwide like VogueQueen’s ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
Breaking Medicine News(10 mins):Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... for new mothers, according to a study in the ... researcher Dr. Robert Whitaker. , While smoking and ... also affect the health of her child, Whitaker said. ... smoking include sudden infant death, asthma, ear infections and ...
... awareness of Molluscum Contagiosum, CHARLES TOWN, W.V., ... RBRM) a provider of treatment for diabetic,peripheral neuropathy ... the month of October 2007; increase is 12% ... "As public awareness of the dangers related ...
... YORK, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- itLinkz Group, Inc.,("ILKZ") ... beginning of,trading today, November 26, 2007, the Company ... Inc." and began trading under its new,symbol (OTC ... a,1:28 reverse split of its outstanding common shares ...
... Giesing, Chief Scientific,Officer and Terry Nida, Chief Operating ... (http://www.urigen.com ) will be featured in an,exclusive ... 27 at 10:30,a.m. EST. The interview will be ... EST on,November 27., The interview will cover ...
... 26, 2007) Rutgers College of Nursing faculty member ... of the Rutgers-Newark Provosts Award for Community Engagement in ... significance based in whole or in part on data ... Diner, Rutgers-Newark provost, established the Provosts Awards for Community ...
... technology allows medical professionals to instantly ... access and manipulate ... a global leader in,software-driven systems for targeted, less-invasive medical ... at the,Annual Meeting of the Radiological Society of North ...
Cached Medicine News:Health News:Smoking and depression often co-occur in new mothers 2Health News:ReBuilder Medical Technologies, Inc. Announces Record Sales Month 2Health News:itLinkz Group, Inc. Changes Name to China YCT International Group, Inc. and Effects Reverse Stock Split 2Health News:WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals 2Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 3
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: